A5041612782- Health Systems, Economic Evaluations, Quality of Life
- Cystic Fibrosis Research Advances
- Inhalation and Respiratory Drug Delivery
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Pharmacy and Medical Practices
- Metabolomics and Mass Spectrometry Studies
- Phase-change materials and chalcogenides
- Air Quality and Health Impacts
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Advanced Drug Delivery Systems
- Family Support in Illness
- Childhood Cancer Survivors' Quality of Life
- Glass properties and applications
- Pharmaceutical Practices and Patient Outcomes
- Climate Change and Health Impacts
- Bacterial biofilms and quorum sensing
- Noise Effects and Management
- Advanced Chemical Sensor Technologies
- Luminescence Properties of Advanced Materials
Swansea University
2018-2025
Cardiff University
2022
University of Hertfordshire
2022
Acquisition of a mucoid phenotype by Pseudomonas sp. in the lungs cystic fibrosis (CF) patients, with subsequent over-production extracellular polymeric substance (EPS), plays an important role mediating persistence multi-drug resistant (MDR) infections. The ability low molecular weight (Mn = 3200 g mol-1) alginate oligomer (OligoG CF-5/20) to modify biofilm structure aeruginosa (NH57388A) was studied vitro using scanning electron microscopy (SEM), confocal laser (CLSM) Texas Red...
Abstract Purpose Outcome-based pricing models which consider domains of value not previously considered in healthcare, such as societal outcomes, are increasing interest for healthcare systems. Societal outcomes can include family-reported outcome measures (FROMs), measure the impact disease upon patient’s family members. The FROM-16 is a generic and easy-to-use quality life tool, but it has never been used context patients undergoing advanced therapy medicinal product (ATMP) treatment. use...
Cystic fibrosis (CF) is an autosomal recessive, life-limiting condition characterized by progressive lung disease, which a major cause of morbidity and mortality for these patients. The inhalation therapy, OligoG CF-5/20, low molecular weight (mean Mn 3200 g/mol) alginate oligomer, with high guluronic acid content (>85%). ability CF-5/20 to enhance the activity antimicrobial/antibiotic therapies, modify rheological properties CF sputum interact mucin, has previously been shown. To further...
<title>Abstract</title> <bold>Purpose</bold>: Outcome-based pricing models which consider domains of value not previously considered in healthcare, such as societal outcomes, are increasing interest for healthcare systems. Societal outcomes can include family-reported outcome measures (FROMs), measure the impact disease upon patient’s family members. The FROM-16 is a generic and easy-to-use quality life tool, but it has never been used context patients undergoing advanced therapy medicinal...
Abstract Background Advance Therapy Medicinal Products (ATMPs) are a novel class of therapeutics that target chronic and severe conditions, which can have an impact beyond the patient themselves; impacting lives partners other family members. This is major secondary burden disease in past has often been ignored. The Family-Reported Outcome Measure (FROM-16) first generic questionnaire designed to measure any on quality life members patients with health condition. We seek validate FROM-16 as...
Abstract Background Advance Therapeutic Medicinal Products (ATMPs) are a novel class of therapeutics to provide more effective treatment conditions or diseases that have not responded conventional treatment. However, ATMPs generally very expensive, limiting their availability. Indicated usually chronic and severe can an impact beyond the patient themselves, impairing lives partners other family members. This is major secondary burden disease often ignored. The Family Reported Outcome Measure...